ACT-335827
ACT-335827 is an orally available, selective orexin 1 receptor antagonist with anxiolytic effects in animals. Unlike other orexin receptor antagonists, ACT-335827 lacks sedative effects and was found to have no impact on sleep architecture in mice.[1][2]
Clinical data | |
---|---|
Routes of administration | Oral |
Drug class | Orexin 1 receptor antagonist |
Identifiers | |
IUPAC name
| |
PubChem CID | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C31H38N2O5 |
Molar mass | 518.654 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
References
- Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (June 2013). "Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist". ChemMedChem. 8 (6): 898–903. doi:10.1002/cmdc.201300003. PMID 23589487. S2CID 21644009.
- Merlo Pich E, Melotto S (2014). "Orexin 1 receptor antagonists in compulsive behavior and anxiety: possible therapeutic use". Frontiers in Neuroscience. 8: 26. doi:10.3389/fnins.2014.00026. PMC 3923148. PMID 24592206.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.